Search Results - "Macoin, Julie"

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis by Rewerska, Barbara, Sher, Lawrence D., Alpizar, Sady, Pauser, Sylvia, Pulka, Grazyna, Mozaffarian, Neelufar, Salhi, Yacine, Martinet, Camille, Jabert, Wafaa, Gudi, Girish, CA, Vinu, GN, Sunitha, Macoin, Julie, Anstett, Victor, Turrini, Riccardo, Doucey, Marie-Agnès, Blein, Stanislas, Konto, Cyril, Machkova, Martina

“…Telazorlimab is a humanized anti-OX40 monoclonal antibody being studied for treatment of T-cell–mediated diseases. This randomized, placebo-controlled, phase…”
Get full text

Generation of homogeneous cell populations with tunable levels of transgene expression by Schlicht, Dominique, Estoppey, Carole, Macoin, Julie, Pouleau, Blandine, Bertschinger, Martin

“…•The generation of homogeneously low expressing recombinant cell populations is a technical challenge.•The generation of multiple cell populations expressing…”
Get full text

GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers by Back, Jonathan, Wermke, Martin, Macoin, Julie, Croset, Amelie, Kauh, John S., Reddy, Venkateshwar

“…Abstract only…”
Get full text

Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma by Drake, Adam, Pihlgren, Maria, Menon, Vinu, Pais, Daniela, Carretero-Iglesia, Laura, Berret, Jeremy, Hall, Olivia, Macoin, Julie, Gruber, Isabelle, Stainnack, Elodie, Estoppey, Carole, Dreyfus, Cyrille, Gudi, Girish, Matsuura, Tomomi, van der Graft, Piet H, Dyson, Michael, Konto, Cyril, Pacaud, Lida, Srivastava, Ankita, Zhukovsky, Eugene, Perro, Mario

“…Despite significant clinical benefit achieved by targeted immunotherapies in recent years, durable responses are still limited in multiple myeloma (MM) 1,2…”
Get full text

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma by Pouleau, Blandine, Estoppey, Carole, Suere, Perrine, Nallet, Emilie, Laurendon, Amélie, Monney, Thierry, Pais Ferreira, Daniela, Drake, Adam, Carretero-Iglesia, Laura, Macoin, Julie, Berret, Jérémy, Pihlgren, Maria, Doucey, Marie-Agnès, Gudi, Girish S., Menon, Vinu, Udupa, Venkatesha, Maiti, Abhishek, Borthakur, Gautam, Srivastava, Ankita, Blein, Stanislas, Mbow, M. Lamine, Matthes, Thomas, Kaya, Zeynep, Edwards, Claire M., Edwards, James R., Menoret, Emmanuelle, Kervoëlen, Charlotte, Pellat-Deceunynck, Catherine, Moreau, Philippe, Zhukovsky, Eugene, Perro, Mario, Chimen, Myriam

“…•ISB 1342 exhibits potent killing of primary MM cells and MM cell lines with low sensitivity to daratumumab.•ISB 1342 induced complete MM tumor eradication in…”
Get full text

ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma by Doucey, Marie-Agnès, Pouleau, Blandine, Estoppey, Carole, Stutz, Cian, Croset, Amelie, Laurendon, Amélie, Monney, Thierry, Pluess, Mégane, Ries-Fecourt, Christelle, Macoin, Julie, Turrini, Riccardo, Suere, Perrine, Mbow, M.Lamine, Nallet, Emilie, Drake, Adam, Perro, Mario, Blein, Stanislas

“…Abstract only 8044 Background: ISB 1342 is a bispecific antibody heterodimer based on the Ichnos proprietary Bispecific Engagement by Antibodies based on T…”
Get full text

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens by Pihlgren, Maria, Hall, Olivia, Carretero, Laura, Estoppey, Carole, Drake, Adam, Pais, Daniela, Loyau, Jeremy, Berret, Jeremy, Gruber, Isabelle, Suere, Perrine, Schnorhk, Vincent, Nallet, Emilie, Pouleau, Blandine, Chimen, Myriam, Macoin, Julie, Stainnack, Elodie, Monney, Thierry, Delachat, Aurore, Dreyfus, Cyrille, Matthes, Thomas, Konto, Cyril, Dyson, Michael, Blein, Stanislas, Mbow, Lamine, Wood, Rebecca, Srivastava, Ankita, Zhukovsky, Eugene, Perro, Mario

Get full text

Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma by Pouleau, Blandine, Estoppey, Carole, Suere, Perrine, Nallet, Emilie, Laurendon, Amélie, Monney, Thierry, Pais Ferreira, Daniela, Drake, Adam, Carretero-Iglesia, Laura, Macoin, Julie, Berret, Jeremy, Pihlgren, Maria, Doucey, Marie-Agnes, Gudi, Girish S, Menon, Vinu, Udupa, Venkatesha, Maiti, Abhishek, Borthakur, Gautam, Srivastava, Ankita, Blein, Stanislas, Mbow, Lamine, Matthes, Thomas, Kaya, Zeynep, Edwards, Claire M, Edwards, James R, Menoret, Emmanuelle, Kervoelen, Charlotte, Pellat-Deceunynck, Catherine, Moreau, Philippe, Zhukovsky, Eugene Alexander, Perro, Mario, Chimen, Myriam

“…Whilst treatment of multiple myeloma (MM) with daratumumab significantly extend patient lifespan, resistance to therapy is inevitable. ISB 1342 was designed to…”
Get full text

Abstract 2970: Overcoming mechanisms of escape from treatments for multiple myeloma with ISB 2001, a potential first-in-class trispecific BCMA and CD38 targeted T cell engager by Pihlgren, Maria, Carretero, Laura, Berret, Jeremy, Hall, Olivia, Estoppey, Carole, Drake, Adam, Pais, Daniela, Macoin, Julie, Chimen, Myriam, Suere, Perrine, Nallet, Emily, Pouleau, Blandine, Stainnack, Elodie, Loyau, Jeremy, Monney, Thierry, Delachat, Aurore, Dreyfus, Cyrille, Blein, Stan, Kaya, Zeynep, Matthes, Thomas, Croasdale-wood, Rebecca, Edwards, James, Edwards, Claire, Mbow, Lamine, Dyson, Michael, Konto, Cyril, Srivastava, Ankita, Zhukovshy, Eugene, Perro, Mario

“…Abstract Immune therapies targeting a single tumor associated antigen (TAA) have demonstrated their efficacy against multiple myeloma (MM) in recent years…”
Get full text

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies by Breton, Caroline S, Nahimana, Aimable, Aubry, Dominique, Macoin, Julie, Moretti, Pierre, Bertschinger, Martin, Hou, Samuel, Duchosal, Michel A, Back, Jonathan

“…CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the…”
Get full text

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells by Carretero-Iglesia, Laura, Hall, Olivia J., Berret, Jérémy, Pais, Daniela, Estoppey, Carole, Chimen, Myriam, Monney, Thierry, Loyau, Jeremy, Dreyfus, Cyrille, Macoin, Julie, Perez, Cynthia, Menon, Vinu, Gruber, Isabelle, Laurendon, Amélie, Caro, Lydia N., Gudi, Girish S., Matsuura, Tomomi, van der Graaf, Piet H., Blein, Stanislas, Mbow, M. Lamine, Croasdale-Wood, Rebecca, Srivastava, Ankita, Dyson, Michael R., Matthes, Thomas, Kaya, Zeynep, Edwards, Claire M., Edwards, James R., Maiga, Sophie, Pellat-Deceunynck, Catherine, Touzeau, Cyrille, Moreau, Philippe, Konto, Cyril, Drake, Adam, Zhukovsky, Eugene A., Perro, Mario, Pihlgren, Maria

“…Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3 + T…”
Get full text

Abstract C164: Preclinical pharmacological characterization of GBR 401, a new monoclonal antibody directed against human CD19 by Hou, Samuel, Blein, Stanislas, Skegro, Darko, Macoin, Julie, Lissilaa, Rami, Back, Jonathan

“…Abstract GBR 401 is a humanized monoclonal antibody directed against domain 2 of human B-lymphocyte antigen CD19 and displays a number of mechanisms which can…”
Get full text